Similar articles

• Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.

  Printz C. Printz C. Cancer. 2013 Sep 1;119(17):3103-4. doi: 10.1002/cncr.28314. Cancer. 2013. PMID: 24037668 No abstract available.
• Androgen deprivation therapy for prostate cancer.

  Bahnson R. Bahnson R. J Urol. 2007 Oct;178(4 Pt 1):1148. doi: 10.1016/j.juro.2007.07.066. Epub 2007 Aug 14. J Urol. 2007. PMID: 17698142 No abstract available.
• Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.

  Takayanagi A, Masumori N, Hashimoto J, Kyoda Y, Yanase M, Tsukamoto T. Takayanagi A, et al. Jpn J Clin Oncol. 2010 Dec;40(12):1154-8. doi: 10.1093/jjco/hyq103. Epub 2010 Jul 20. Jpn J Clin Oncol. 2010. PMID: 20647233
• Intermittent androgen deprivation.

  Dawson NA. Dawson NA. Curr Oncol Rep. 2000 Sep;2(5):409-16. doi: 10.1007/s11912-000-0060-6. Curr Oncol Rep. 2000. PMID: 11122872 Review.
• Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.

  Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais da Silva F. Sciarra A, et al. Eur Urol. 2013 Nov;64(5):722-30. doi: 10.1016/j.eururo.2013.04.020. Epub 2013 Apr 19. Eur Urol. 2013. PMID: 23628492 Review.